ClinicalTrials.gg
Not yet recruitingNCT07859709Updated Oct 6, 2026

The CLASP III TR CED Study

An observational study in Tricuspid Regurgitation, Heart Valve Diseases and Heart Diseases, sponsored by Edwards Lifesciences. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Edwards Lifesciences · Observational

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,350
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences — 3 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Edwards Lifesciences.

Started
2026
the only one that year
Observational
5 of 14
3 open now
Registered
14th of 14
by date

Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, this one is the only one that started in 2026, is one of 5 observational ones, and was the 14th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

3 of the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Repair procedure using the PASCAL Precision system.

Read the detailed description

This is a prospectively designed, retrospective non-randomized cohort study to measure the 2-year effectiveness of the PASCAL Precision Transcatheter Valve Repair system ("PASCAL Precision system") for the treatment of at least severe tricuspid regurgitation in the real world.

This study will evaluate patients treated with the PASCAL Precision system who have at least severe Tricuspid Regurgitation as compared to Medicare eligible untreated patients. Analysis will be completed using a large, de-identified, claims and electronic health record (EHR) database and supplemented with registry and other claims data.

The primary outcome will also be assessed in various pre-defined subgroups.

03

Conditions studied

  • Tricuspid Regurgitation
  • Heart Valve Diseases
  • Heart Diseases
  • Cardiovascular Diseases
  • Tricuspid Valve Insufficiency

Keywords

  • PASCAL
  • Coverage with Evidence Development
  • CED
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Medicare eligible real-world patients with severe tricuspid regurgitation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medicare eligible patients, 65 years old or older
  • With at least severe Tricuspid Regurgitation who have either received PASCAL Precision system or been managed medically with no transcatheter or surgical tricuspid valve intervention

Exclusion criteria

Exclusion Criteria:

  • Patients not eligible for Medicare (i.e., under 65 years old)
  • Patients with less than severe Tricuspid Regurgitation
  • Patients who have received a transcatheter or surgical intervention other than PASCAL Precision system
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,350 participants (estimated)
Patient registry
No

Groups and cohorts

  • PASCAL Precision system Treated

    Patients 65 years old or older with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Repair with the PASCAL Precision system.

    Device: PASCAL Precision system Treated

  • Medicare Eligible Untreated Patients

    Patients 65 years old or older with at least severe Tricuspid Regurgitation who did not receive any transcatheter or surgical tricuspid valve intervention.

    Other: Medicare Eligible Untreated Patients

Interventions

  • DevicePASCAL Precision system Treated

    Patients 65 years old or older with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Repair with the PASCAL Precision system.

  • OtherMedicare Eligible Untreated Patients

    Patients 65 years old or older with at least severe Tricuspid Regurgitation who did not receive any transcatheter or surgical tricuspid valve intervention.

06

What researchers measure

Primary outcomes

  1. Composite (All-Cause Death or Heart Failure Hospitalization)

    Time to death or heart failure hospitalization after time zero

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2030, 50 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 6, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Oct 31, 2033
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859709
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Oct 31, 2033 (estimated)
Last update
Oct 6, 2026

Study contacts

TMTT GHER
Contact
TMTT_GHER_Evidence@edwards.com
949-250-2500

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion